Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277836 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00277836 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT00277836, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.
Interventions
- DRUG MST-997
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277836
The ClinicalTrials.gov registry entry for NCT00277836 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MST-997 is the first listed.
NCT00277836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277836 about?
NCT00277836 is a clinical study titled "Study Evaluating MST-997 in Advanced Malignant Solid Tumors". MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-9...
What is the current status of trial NCT00277836?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00277836?
The interventions under investigation include: MST-997 (DRUG).
Who is sponsoring clinical trial NCT00277836?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.